Igenica to Advance mAb Platform with $33M Series C
By Marie Powers
Wednesday, June 13, 2012
Privately held Igenica Inc. hooked Third Rock Ventures LLC, which traditionally launches biotech start-ups, as lead investor in a $33 million Series C to propel initial monoclonal antibody (mAb) candidates toward the clinic.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.